Jules Lipoff, MD
Dermatology · Philadelphia, PANPI 1255644365
Payments from drug & device makers
What this record shows
This record is dominated by grants: $250,306 of the $258,596 with a category attached, or 96.8%. Pfizer accounts for 96.6% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $251,604 and has fallen 98.2% since, to $4,468 in 2025. Among dermatology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 12 payments — averaging $21,550 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$250K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- Boehringer Ingelheim$2K
- Amgen$2K
- Novartis$453
- AbbVie$68
- plus $26 from 1 others
What the payments were for
- Consulting fees$8,1233%
- Grants$250,30697%
- Food & beverage$1670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 1 | $249,926 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $3,990 |
| Boehringer Ingelheim | 1 | $2,480 |
| Amgen | 1 | $1,653 |
| Novartis | 4 | $453 |
| AbbVie | 3 | $68 |
| LEO Pharma Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Otezla$1,653
How this compares
$258,596 in reported general payments places this provider in the 95th percentile of 626 dermatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 84 | $320,008 |
| Cosentyx Unoready PenSecukinumab | 15 | $172,835 |
| Dupixent SyringeDupilumab | 20 | $75,689 |
| Clobetasol Propionate | 115 | $8,464 |
| Tacrolimus | 53 | $8,058 |
| Triamcinolone Acetonide | 145 | $2,137 |
| Ketoconazole | 119 | $1,960 |
| Clindamycin Phosphate | 55 | $1,919 |
| Betamethasone Dipropionate | 40 | $1,398 |
| Tretinoin | 37 | $1,226 |
| Doxycycline Hyclate | 24 | $749 |
| ValacyclovirValacyclovir Hcl | 17 | $388 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 34 | $350 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 13 | $341 |
| Minoxidil | 39 | $318 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Philadelphia
- Stephen HessPhiladelphia$1.7M
- Joel GelfandPhiladelphia$649K
- Victoria WerthPhiladelphia$547K
- Nicholas MollanazarPhiladelphia$369K
- Harold FarberPhiladelphia$284K
- Susan TaylorPhiladelphia$207K
- Joy WanPhiladelphia$176K
- Harold MilsteinPhiladelphia$120K
- David MargolisPhiladelphia$118K
- Naeha GuptaPhiladelphia$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.